Msi

• Microsatellite Instability (MSI) refers to genetic alterations in short, repetitive DNA sequences due to a faulty DNA mismatch repair system.
• MSI is a hallmark of certain cancers, most notably colorectal, endometrial, and gastric cancers.
• Testing for MSI helps identify patients with hereditary cancer syndromes like Lynch syndrome.
• MSI status is a significant biomarker for predicting response to immune checkpoint inhibitor therapies.
• Diagnosis typically involves PCR-based assays, immunohistochemistry (IHC), or next-generation sequencing (NGS).

What is Microsatellite Instability (MSI)?

Microsatellite Instability (MSI) refers to a condition where there are errors in the replication of microsatellites, which are short, repetitive sequences of DNA found throughout the human genome. These errors typically occur when the DNA mismatch repair (MMR) system, responsible for correcting mistakes made during DNA replication, is not functioning properly. A deficient MMR (dMMR) system leads to the accumulation of these errors, resulting in changes in the length of microsatellite sequences within tumor cells.

The presence of MSI is a significant molecular signature in oncology, indicating a hypermutated tumor phenotype. This genetic instability can drive cancer development and progression. MSI is categorized into Microsatellite Instability-High (MSI-H), Microsatellite Instability-Low (MSI-L), and Microsatellite Stable (MSS), with MSI-H being the most clinically relevant as it signifies a widespread defect in the MMR system.

Causes and Clinical Significance of MSI

MSI can arise from two primary mechanisms. Firstly, it can be due to germline mutations in MMR genes (such as MLH1, MSH2, MSH6, and PMS2), which are inherited and cause hereditary cancer predisposition syndromes like Lynch syndrome. Secondly, MSI can occur sporadically in tumors due to somatic mutations or epigenetic silencing (e.g., methylation of the MLH1 promoter) of MMR genes, meaning the defect is acquired within the tumor cells and is not inherited.

The clinical significance of MSI is profound and multifaceted. MSI status serves as a critical biomarker for:

• Prognosis: In early-stage colorectal cancer, MSI-H tumors are often associated with a better prognosis compared to MSS tumors.
• Therapeutic Guidance: MSI-H tumors are highly responsive to immune checkpoint inhibitors (immunotherapy), regardless of the cancer type. This has revolutionized treatment for many patients with advanced MSI-H cancers, including colorectal, endometrial, and gastric cancers.
• Lynch Syndrome Screening: MSI testing is a standard screening tool to identify individuals who may have Lynch syndrome, prompting further genetic testing and family counseling.

According to the National Cancer Institute (NCI), approximately 15% of all colorectal cancers exhibit MSI-H, and about 3-5% of all colorectal cancers are linked to Lynch syndrome. MSI-H is also observed in 20-30% of endometrial cancers and 10-20% of gastric cancers, among others.

Diagnosis and Testing for MSI

Accurate diagnosis of MSI is essential for appropriate patient management. Several methods are commonly employed to determine MSI status:

1. PCR-based Assays: This is a traditional and widely used method. It involves comparing the lengths of specific microsatellite markers in tumor DNA with those in corresponding normal tissue DNA. Instability at two or more of the five standard markers (BAT-25, BAT-26, D5S346, D2S123, and D17S250) classifies a tumor as MSI-H.
2. Immunohistochemistry (IHC): IHC staining assesses the expression of the four main MMR proteins (MLH1, MSH2, MSH6, and PMS2) in tumor tissue. Loss of expression of one or more of these proteins indicates a deficient MMR (dMMR) system, which strongly correlates with MSI-H status.
3. Next-Generation Sequencing (NGS): Advanced NGS panels can simultaneously detect MSI status and identify mutations in MMR genes. This method offers comprehensive molecular profiling and is increasingly used in clinical practice due to its ability to provide broader genomic insights.

The results of MSI testing classify tumors as MSI-High (MSI-H), MSI-Low (MSI-L), or Microsatellite Stable (MSS). MSI-H indicates a significant defect in the MMR system, while MSI-L shows instability at only one marker and is often grouped with MSS for clinical decision-making. Testing for MSI is routinely recommended for patients with colorectal, endometrial, and gastric cancers, and its utility is expanding to other solid tumors to identify candidates for immunotherapy.